obesity treatment
-
Novo Nordisk Gains Momentum with GLP-1 Drug Expansion
The success of GLP-1 therapies like Ozempic and Wegovy has propelled Novo Nordisk’s stock, reflecting surging global demand for obesity solutions.
-
Novo Nordisk Boosts Oral GLP-1 Production Amid Intensifying Competition
Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.
-
Wegovy Pill Launches: Oral GLP-1 Reshapes Weight Loss Management
Novo Nordisk’s Wegovy pill, the first oral GLP-1 for weight loss, is now broadly available, offering a new, convenient option for millions battling obesity. Learn about its efficacy, cost, and availability.
-
Wegovy Pills Set to Transform Weight Loss Market Amid Cost and Accessibility Concerns
Novo Nordisk’s new Wegovy pill is set to launch in the US, promising more accessible weight loss treatments for those who avoid injections. Yet, high prices and insurance barriers remain major obstacles for millions seeking medical help for obesity.
-
GLP-1 Drugs Show Mixed Results for Employers on Medical Costs
A new study finds that while GLP-1 drugs like Wegovy and Ozempic aid weight loss, they increase medical costs over two years, raising concerns for employers.